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Abstract
Introduction Costs are one of the factors determining physicians’ choice of medication to treat
patients in specific situations. However, usually only the drug acquisition costs are taken into account,
whereas other factors such as the use of disposable materials, the drug preparation time and the staff
workload are insufficiently taken into consideration. We therefore decided to assess true overall costs
of intravenous (IV) antibiotic administration by performing an activity-based costing approach.
Methods A prospective survey on costs and workload by means of a time and motion analysis and
activity-based costing was performed in a 605-bed secondary referral centre with 20 intensive care unit
beds. The subjects were 50 consecutive patients admitted to our hospital with community-acquired
pneumonia or intra-abdominal infections requiring treatment with IV antibiotics. A time and motion
analysis of 103 routine acts of preparing and administering IV antibiotics was performed in the intensive
care unit and in the Department of Internal Medicine. To measure the entire process an inventory and
work flowchart were made using detailed questionnaires completed by members of the nursing staff, the
medical staff and the pharmacy staff. In addition, questionnaires were distributed to management and
secretarial staff to determine additional overhead costs. The average costs for different methods of IV
antibiotic administration were then compared by timing all steps in the process. Four different methods
of drug administration were used: administration by volumetric pump, administration by syringe pump,
administration by ‘unaided’ infusion bag, and administration by direct IV injection.
Results  The average times required for each of these procedures, including preparation and
administration of the drug, were 4:49±2:37, 4:56±2:03, 5:51±3:33 and 9:21±2:16 min (mean
minutes:seconds±standard deviation), respectively. When the costs for expended staff time and
materials (not including drug costs) were calculated this resulted in average costs of €5.65, €7.28,
€5.36 and €3.83, respectively, for administration of each dose of antibiotics. These costs represent
between 11% and 53% of the total daily costs of antibiotic therapy. Compared with the acquisition
costs, these indirect costs ranged from 13% to 113%. Not included in this comparison is the time
required for insertion of an IV catheter, which was found to be 10:15±6:31 min with an average
calculated cost of €9.17.
Conclusions Total costs of IV antibiotic administration are formed not only by the costs of the drugs
themselves, but also, to a substantial degree, by the time expended by medical and nursing staff, costs
of disposable materials and overhead costs. Physicians making decisions regarding the use of specific
medications in intensive care unit patients should take these factors into account. Use of IV antibiotics
is associated with considerable workload and additional costs that can exceed the acquisition costs of
the medications themselves.
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Introduction
A number of studies have suggested that the overall quality of
care, outcome, and patient and family satisfaction in intensive
care units (ICUs) may be linked to the workload and staffing
levels [1–4]. Budgetary restrictions may play an important
role in the organisation of the ICU, and cost reduction is an
important issue in intensive care medicine today since ICU
costs account for up to 10% of overall hospital expenditure
[5,6].
Antibiotics are among the most frequently used drugs in
intensive care patients, and thus account for a substantial
proportion of drug expenditure in ICUs [7]. When performing
pharmacoeconomic evaluations of ICU expenditure, it is cus-
tomary to consider only the direct price of purchasing these
medications. To assess the total costs of intravenous (IV)
drug therapy in the ICU setting, however, it is necessary to
take into account the effect on the workload of nurses and
medical staff as well as other health care workers, and to
evaluate other costs associated with preparation, administra-
tion and monitoring of IV antibiotic therapy. Gaining insight
into all the factors that contribute to the actual total overall
costs of drug therapy may help increase awareness into what
actually drives the costs of hospital services, and to identify
opportunities for cost savings.
To assess the costs associated with drug preparation and
administration we performed an observational time and
motion study in two ICUs in our hospital. For comparison, we
also performed this analysis in a general internal medicine
ward. The basis of a time and motion study is the measure-
ment, through direct observation by the investigators and the
research nurses involved in the study, of staff members per-
forming specific tasks in a process that is subdivided into
various components [8]. Indirect costs related to drug
therapy, such as costs incurred in assessment of safety and
efficacy, were not considered in this study.
Materials and methods
This time and motion analysis was conducted from December
2000 until June 2001 in Gelderse Vallei Hospital, a 605-bed
secondary referral centre in The Netherlands.
Activity-based costing is a method originally developed for
business administration that is increasingly being used in the
health care environment and in hospital administration. Its
goal is to determine the actual costs that need to be incurred
to deliver a product or service, and to assess and quantify the
various components making up the total cost [9,10]. We
used activity-based costing to calculate the actual costs of
treating patients with IV antibiotic therapy. The costs were
subdivided into four components: the acquisition costs of
drugs; the costs of the disposable materials used; the costs
related to the use of medical and nursing staff, calculated by
multiplying the time expended by individual staff members to
perform specific tasks by the costs of employing these staff
members (wages, fringe benefits and taxes); and the alloca-
tion of indirect costs such as overheads, use of storage
space and the electricity used.
Questionnaires were initially given to hospital staff, and inter-
views were conducted to assess and record the entire process
related to the administration of IV antibiotics. This preliminary
analysis was performed in order to develop appropriate data
transcription forms, to obtain data on salaries and material
costs, and to identify additional factors contributing to total
costs. The questionnaires, in combination with existing proto-
cols, were then used to compile an extensive list of all the sepa-
rate actions that were required for the preparation and
administration of each of the medications studied, and for each
of the methods of drug administration used in our hospital.
Fifty consecutive patients requiring treatment with IV antibi-
otics who were admitted to the ICU (n=22), to the high care
unit (HCU) (n=24) or to the internal medicine ward (n=4)
with community-acquired pneumonia or intra-abdominal infec-
tions were included in the study. No specific exclusion criteria
were used as this study aimed at the process of, and not at
the indications or efficacy of, IV antibiotic administration.
Informed consent was obtained from the patient or relatives
according to the hospital’s ethical guidelines and the declara-
tion of Helsinki.
A total of 103 routine acts of preparing and administering IV
antibiotics were observed and timed by stopwatch by two
research nurses familiar with IV antibiotic preparation and
administration while observing 76 single (ICU) nurses per-
forming the 103 procedures of preparation and administra-
tion of the antibiotics. The preparation and administration of
IV antibiotics in our hospital is performed by nurses. No satel-
lite pharmacy is available on wards and there are no IV addi-
tive services by the Department of Pharmacy.
Four pharmacists and two technicians were involved in the
study. Preparation and administration of antibiotics were mea-
sured separately. The time intervals as well as the materials
used were recorded on data transcription forms. The medica-
tions studied were six of the most widely used IV antibiotics:
amoxicillin/clavulanic acid, piperacillin/tazobactam, cefotaxim,
metronidazole, gentamicin and erythromycin. Four different
methods of administration were studied: infusion by syringe
pump, infusion by volumetric pump, infusion by direct IV injec-
tion (bolus injection, IV push injection), and simple piggyback
infusion (medication added to infusion bag of an ordinary
drip). Actions associated with the insertion and removal of a
peripheral IV catheter were studied separately because most
patients in the ICU already have venous access.
Cost assessment
The data recorded on the data transcription forms were used
as the basis for the assessment of costs of preparation and of
administration. Average total costs for each of the differentR186
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methods of drug administration were calculated by consider-
ing the following cost components.
Wages
Yearly salaries for relevant staff members were converted to
hourly wages by dividing the yearly income by the number of
‘workable hours’. These hourly wages were then used to
convert time measurements into costs per procedure.
Costs for disposable material
The average numbers of items used for each procedure were
multiplied by unit prices to arrive at average total costs for
disposable material for each procedure.
Other costs
Estimates were made to determine the impact of other costs
on total costs by considering the categories ‘monitoring activ-
ities’, ‘infusion pumps’, ‘administrative costs’, ‘storage, distrib-
ution and inventory’, and ‘waste disposal’.
A number of potential additional costs were disregarded
because they were assumed not to be directly related to the
IV administration route and for various other reasons, includ-
ing the following:
• Overhead costs associated with storage, distribution and
inventory. As already stated, these costs were considered
insignificant compared with the other costs involved, and
were assumed to be the same for different types of med-
ication, and for both oral or IV medications.
• The processing of a prescription for IV antibiotics. This
procedure is the same for all types of prescriptions.
• Time spent by the head of the hospital pharmacy on
quality assurance, providing advice regarding antibiotic
therapy, developing protocols, and so on. These costs
were considered unavoidable in any type of therapy, and
were considered central to the task of the pharmacy.
• Costs for disposal of waste. IV administration of antibi-
otics obviously generates ‘extra’ waste, such as empty
syringes, IV tubing, gauzes and needles, and so on.
Although this waste is collected and disposed of as part
of a general system of waste disposal in the hospital,
some of the costs associated with the maintenance of this
system should probably be allocated to IV antibiotics
administration. We decided not to allocate these costs
because they could not be exactly calculated, and there-
fore allocation would involve a more or less random esti-
mate. The additional costs incurred for waste disposal are
unlikely to significantly affect the overall differences in
costs; in addition, disposal costs are higher for IV medica-
tions, so any differences observed in the present study
are probably underestimated.
• Costs associated with complications related to access to
the blood stream. The risks of IV access, especially
through central venous catheters, are well recognised and
represent an important issue for physicians working in the
ICU. The most important of these is infection, which can
lead to significant morbidity, mortality and extra costs
[11–15]. Another significant potential problem is needle
stick injury. However, the magnitude of the costs due to
such hazards, and what proportion of these costs should
be attributed to IV antibiotics therapy, would again involve
a more or less random estimate. Moreover, our study was
not designed to address this issue. Therefore, these costs
were also not taken into account.
Statistics
Calculations and statistical analysis were performed using
Excel and SSPS9 software for Windows. All data are
expressed as the mean±standard deviation. Student’s
unpaired t test was used for comparisons between the differ-
ent modes of antibiotic preparation and antibiotic administra-
tion. Costs were calculated and compared both including and
excluding the costs of the antibiotics themselves. Costs asso-
ciated with the insertion and removal of central and/or periph-
eral intravascular devices were analysed separately.
Statistical significance was accepted for P<0.05.
Results
Thirty-four male patients (mean age, 72 years; range,
35–86 years) and 16 female patients (mean age, 55 years;
range, 31–87 years) were included in the study. A total of
103 procedures for IV antibiotic administration were
observed in these patients. Community-acquired pneumonia
was diagnosed in 35 patients (70%) and intra-abdominal
infections diagnosed in 15 patients (30%). Overall, 45 proce-
dures (44%) were observed in the ICU, 46 procedures
(45%) in the HCU and 12 procedures (12%) in the general
internal ward. The data were initially analysed separately;
when no significant differences were found between the ICU,
the HCU and the internal medicine ward, the data were
pooled.
Table 1 presents the times required for each of the subcate-
gories of procedures, the expenditure on hourly wages
(depending on location and category of staff involved), the
costs for disposable material and the resulting total costs per
procedure. The figures depict the total time expended on
preparation and administration of the study medications, aver-
aged over the different medications, the different wards and
the different reasons for starting antibiotic therapy. No med-
ication costs are included.
Results are based on the following yearly average wages:
ICU nurse, €36,211.66; HCU nurse, €31,093.02; ward
nurse,  €29,895.04; pharmacist, €92,189.99; pharmacy
technician,  €31,528.65; ward assistant, €21,454.73; and
consulting physician, €108,907.25.
By adding up costs for each type of procedure the following
total costs per procedure were obtained: €3.91 for volumet-
ric pump administration, €3.23 for syringe pump administra-
tion,  €11.69 for direct IV administration, €5.40 for piggyR187
back infusion, €8.32 for the insertion of an IV catheter and
€1.74 for the removal of an IV catheter. No observations
using central venous catheters were made. Again, it should
be emphasised that these costs do not include the costs of
the drugs themselves. Direct IV administration is time con-
suming due to fact that the antibiotic has to be infused slowly,
and costs are high because only certified nurses or physi-
cians are allowed to perform such procedures.
Although it was not possible to precisely determine costs
incurred by other categories of activities—such as storage
space, time spent by other personnel (e.g. pharmacy techni-
cians), unallocated time, depreciation of medical equipment
(e.g. infusion pumps) and overheads—it was estimated that
these other costs were minor compared with personnel costs
and material costs. Monitoring for IV antibiotics therapy in
general does not take up much time and is usually performed
between other nursing activities. Procedures that pertain to
the maintenance of an IV access port cannot be considered
due to antibiotics therapy in ICUs, as all patients will require
an IV access site for various other purposes. The same
applies to dealing with the complications that are caused by
central venous catheters. On general wards, however, an IV
catheter may be inserted with the specific goal of administer-
ing antibiotics. Costs due to monitoring and complications in
such cases could therefore, in principle, be allocated to the
administration of IV antibiotics.
Costs associated with the monitoring of drug levels through
assessment of serum levels of gentamicin were estimated
based on the materials used and the staffing time costs for
the blood sampling, the measurement of drug levels, the time
used for kinetic modelling using MW/Pharm software (Medi-
ware, Zuid-Hoorn, The Netherlands) and the time for recom-
mending the optimal dosing strategy. Calculated in this way,
the costs for therapeutic drug monitoring were €36.00 per
dose based on a once-daily gentamicin dosage. These costs
would decrease proportionately if longer dosing intervals
were used.
The equipment used to administer IV drugs is quite expensive
and requires maintenance. Gelderse Vallei Hospital uses
Braun Infusomat® fmS volumetric pumps and Braun
Perfusor® fm syringe pumps (Braun Medical AG, Melsungen,
Germany). The depreciation period is set at 10 years (10%
per year). If maintenance costs are disregarded, the cost is
less than €0.34 per administration procedure.
The pharmacy of the hospital processes about 170,000 pre-
scriptions per year, with one prescription requiring about
3–5 min of work by a pharmacy assistant. The number of
administrations per prescription should divide this time. In
general, one prescription will lead to at least 10 administra-
tions (two per day for 5 days), so costs of less than €0.17
can be allocated to the pharmacy cost item.
Average times required for preparation and administration of
antibiotics showed an ascending order from the ICU to the
HCU to the internal medicine ward. A subanalysis of cases
where the same drug was administered according to the same
method on different wards revealed a number of nonsignificant
trends toward smaller time expenditure in the ICU. For
example, a difference between average times required for
administration of erythromycin via a volumetric pump in the
ICU and in the HCU was noted (8:21±2:38 min versus
9:7±2:21 min, P=0.38). For cefotaxim administration via
syringe pump these values are 4:2±2:3min versus
4:53±0:36min, respectively (P=0.13). However, our study
was not designed to detect differences between various units.
Table 2 presents the workload, the staff costs, the material
costs, the medication costs and the total costs for the six dif-
ferent antibiotics studied. A marked difference in costs of ery-
thromycin administration compared with the other antibiotics
Available online http://ccforum.com/content/7/6/R184
Table 1
Total costs of intravenous antibiotic administration using different methods of administration
Procedure Time required Hourly Time Materials Total
(standard deviation) (min:s) wages (€) costs (€) costs (€) costs (€)
Volumetric pump 5:04 (2:29) 21.90 01.85 02.06 03.91
Syringe pump 4:56 (2:03) 21.58 01.78 01.45 03.23
Bolus injection 9:21 (2:16) 74.09 11.59 00.10 11.69
Piggyback infusion 5:51 (3:33) 19.75 01.93 03.47 05.40
Insertion of intravenous catheter 10:15 (6:31) 23.51 04.02 04.30 08.32
Removal of intravenous catheter 02:22 (0:36) 19.41 00.74 01.00 01.74
Data presented are the time expenditure required for each of the procedures considered, the appropriate hourly wage rates (depending on the
ward and the type of staff involved), the costs for disposable material and the resulting total costs per procedure. The values quoted refer to the
total time for preparation followed by administration of the medication, averaged over medications, wards and indications studied. No medication
costs are included.R188
is primarily due to the relative insolubility of erythromycin
powder, requiring significantly longer preparation times. The
short preparation time for metronidazole is due to the fact that
it is delivered as a 0.5% solution contained in a 100ml bottle
ready for infusion. This is the only drug in the study that is
prepared by the hospital pharmacy.
Discussion
The results of the present study demonstrate that administration
of antibiotics is associated with significant hidden costs, which
in some cases even exceed the costs of the antibiotics them-
selves. This is due mainly to the fact that medical staff and,
especially, nursing staff spend a considerable amount of time
preparing and administering the medications chosen for the
study. Although the scope of the study was limited to antibiotics,
our results probably also apply to other types of medication.
In the ICU setting, patients in ICUs with a high workload are
significantly more likely to die than patients in ICUs with a
lower workload, even after adjustment for severity of illness
[2,3]. Other studies have demonstrated that the time required
for weaning off the ventilator in patients with severe chronic
obstructive pulmonary disease is dependent on the availabil-
ity and time of (qualified) nurses [4]. In addition, the degree of
satisfaction with the ICU care of patients and their families
appears to be related to staffing levels and to workload [1].
All these factors underscore the importance of controlling the
workload as well as the costs associated with the administra-
tion of antibiotics, as well as other types of medications.
Decreasing this type of workload will allow health care
workers to spend more time on other aspects of patient care,
which would probably improve outcome and overall care of
ICU patients and their families.
The present results demonstrate that the workload required
for drug preparation and administration should be taken into
account when performing an overall cost assessment. This
also applies to costs incurred from usage of disposable mate-
rials; in fact, the workload and costs for disposable materials
were important cost drivers in our study, accounting for
13–53% of the overall costs for treatment with IV antibiotics
and for 13–113% of the total acquisition costs of medication.
Moreover, our study probably overestimates the contribution
of acquisition costs to overall costs because list prices were
used to determine acquisition costs. In The Netherlands (as
in most other European countries) hospitals often negotiate
price reductions varying from 20% to 70% of listed prices for
IV antibiotics. We did not take this into account because of
the variable nature of these discounts; however, the impact
on the overall prices is probably substantial. In addition, differ-
ences in costs have probably been underestimated because
additional costs incurred by central line infections and waste
disposal were not taken into account for the reasons outlined
in Materials and methods.
When performing pharmacoeconomic evaluations of IV anti-
biotics administration it is thus important to include costs
associated with preparation and with administration, as these
can be the major cost drivers. This is exemplified by a study by
Kreter [16], who demonstrated that acquisition costs of
imipenem-cilastatin monotherapy were considerably higher
compared with clindamycin/aminoglycoside combination
therapy for treatment of serious lower respiratory infections,
intra-abdominal infections, gynaecologic infections and urinary
tract infections. When costs at that moment related to prepa-
ration, to administration and to monitoring of both regimens
were also taken into account, however, the overall costs of the
two antibiotic regimes were not significantly different [16].
Our observations of high costs incurred by bolus injection
administration of antibiotics are in contrast with the widely
held view that this is the cheapest method of administration.
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Table 2
Daily costs of six antibiotics intravenously administered by syringe pump
Total daily 
Dose Dosages Drug Average Staff Material Administration costs (€)
Antibiotic (mg) (n) costs (€) (A) time (min:s) costs (€) (B) costs (€) (C) costs (€) (B + C) (A + B + C)
Amoxicillin/clavulanic 1000/200 3 07.35 12:21 03.99 04.35 08.34 15.69
acid
Cefotaxim 1000 4 49.40 18:48 06.08 05.80 11.88 61.28
Erythromycin 1000 4 54.44 36:44 11.88 05.80 17.68 72.12
Gentamicin 320 1 20.34 03:39 01.18 01.45 02.63 22.97*
Metronidazole 500 3 12.24 05:24 01.74 04.35 06.09 18.33
Piperacillin/tazobactam 2250 3 43.14 16:31 05.40 04.35 09.75 52.89
Data presented are the medication costs, the time expenditure required, the staff wage and the disposable material costs for each of the antibiotics
per day administrated via syringe pump. The figures quoted refer to the total time for preparation and administration of each medication per day,
averaged over wards and indications studied. Costs are based on list prices provided by Dutch health care authorities [17].
*If therapeutic drug monitoring costs for gentamicin based on 24-hourly intervals would be included, the total costs would be €58.97 per day.R189
Several factors can account for this observation. Most anti-
biotics used in our study had to be administered slowly, imply-
ing a longer time period required for complete administration
coupled with higher staff costs. On the contrary, during piggy
back infusion we did not count the total duration but only
those moments that could be related to the process of prepa-
ration, of administration and of monitoring of the infusion.
In addition, as explained earlier, a number of additional costs
were not taken into account in the present study because it
was not possible to obtain exact measurements. These
included costs for waste disposal and costs associated with
catheter-related complications or other problems. Although
not measured in this study, these costs are probably consider-
able [11–15]. Therapeutic drug monitoring for a single mea-
surement of gentamicin levels was previously estimated by
other workers to be approximately €25 [18] and was found to
be  €36 in our study. The difference is explained by cost
increases over time and by the fact that we included the time
used for obtaining the blood sample and for the kinetic model-
ling. If costs related to aminoglycoside-induced nephrotoxicity
are taken into account the amount would be considerably
higher [18]. The calculations in our study thus almost certainly
substantially underestimate the contribution of nonacquisition
costs to the overall costs of antibiotic therapy. Further studies
will be required to adequately assess the importance of yet
other potential cost factors, which might even include costs
due to medical errors and other complications of IV therapy.
The present study evaluated only monotherapy antibiotic regi-
mens. However, ICU patients often develop complex infec-
tions that are difficult to treat, and they often require
combinations of different IV antibiotic formulations. It seems
probable that such regimens will require disproportionately
more time for preparation and for administration, thereby sig-
nificantly increasing the workload and costs. Moreover, such
treatments may require insertion of a central venous catheter,
increasing costs even further. As already discussed, signifi-
cant additional costs (up to €20,000) may be incurred if the
patient develops a central line infection [11–13].
In the present study it proved difficult to accurately determine
what overhead costs were directly related to IV antibiotic
therapy. In addition, the design of the study did not allow an
accurate evaluation of sources of variation. Nevertheless, the
results indicate that these costs varied according to the
department, to the category of staff involved (differential
wage rates) and to the type of medication administered (due
to differences in preparation time). These variables, however,
are not independent; we observed a trend toward longer
preparation and administration time in general wards, but
lower nursing staff wages compared with ICU nurses in part
compensated the costs for this.
Strategies to reduce total costs of IV antibiotics may include
the use of single daily dose regimens, the reduction of treat-
ment duration, the use of drugs with low toxicity so that moni-
toring of drug levels is not necessary and the use of quickly
dissolvable drug powders and/or ready-to-use-vials or
syringes. Furthermore, rational antibiotic therapy policies that
take these aspects into account can help promote a benefi-
cial economic impact without adverse effects on outcome
[19]. It should be noted that, at present, there is an increasing
tendency to switch from the IV route to the oral route for
administration of antibiotics at an early stage of therapy [20].
This strategy may help reduce costs. However, this requires
that the patient is capable of oral intake, that the antibiotic is
suitable for oral use and has a high bioavailability, and that
the patients’ intestinal function is intact. Especially in inten-
sive care patients there is insufficient evidence that such a
strategy is safe and effective.
A limitation of the present study is that the calculations are
based on the Dutch situation, using Dutch wages and Dutch
medication prices. These costs are unlikely to be completely
different in other European countries, however, and our
observation that nondrug costs are important cost drivers in
IV antibiotic use in the ICU almost certainly also apply to
other countries.
In conclusion, we observed that the indirect costs of IV antibi-
otic administration such as the workload and the use of dis-
posable materials are considerable. Our findings are probably
also applicable to medications other than antibiotics. In our
opinion this type of cost should be taken into account when
determining the overall expenditure for specific therapies, and
physicians should become more aware of such ‘hidden’
costs. Significant cost savings could potentially be realised
by taking these factors into account when choosing a spe-
cific medical therapy, and by developing alternative methods
of preparation and administration that require less work and
less use of disposable materials. Apart from the financial
aspect such reductions in time and workload may help
improve outcome and patient satisfaction in the ICU, espe-
cially in situations of high workload and limited resources.
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